Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 4/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 3/20 | 0.38 |
| ▸ | GABRD | O14764 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.38 |
| ▸ | GABRE | P78334 | 3/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28094810 | 1.00 | ENPEP (0.46) | ENPEPFOLH1ALDH1A1GABRPGABRD | |
| SCHEMBL5543062 | 0.88 | GABRP (0.45) | ENPEPFOLH1GABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL28266647 | 0.86 | GABRP (0.43) | ENPEPFOLH1GABRPGABRDGABRA1 | |
| SCHEMBL27826930 | 0.84 | ENPEP (0.48) | ENPEPFOLH1ALDH1A1GABRPGABRD | |
| SCHEMBL17030111 | 0.79 | GABRP (0.41) | ENPEPFOLH1ALDH1A1GABRPGABRD | |
| SCHEMBL910782 | 0.78 | ITGB3 (0.40) | ENPEPGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29242708 | 0.77 | ENPEP (0.46) | ENPEPFOLH1ALDH1A1GABRPGABRD | |
| SCHEMBL15543759 | 0.77 | ENPEP (0.46) | ENPEPFOLH1ALDH1A1GABRPGABRD | |
| SCHEMBL7414549 | 0.76 | CYP1A2 (0.47) | ALDH1A1CYP1A2TSHRKMT2ANPSR1 | |
| SCHEMBL2333422 | 0.76 | ALDH1A1 (0.44) | ENPEPALDH1A1GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105724826-B | A kind of prawn feed additive and its application | 集美大学 | 2019-11-26 | — | — | CN | claimed |
| CN-105873581-A | vasodilator formulations and methods of use | ATP研究有限公司 | 2016-08-17 | — | — | CN | claimed |
| US-20030055053-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives | PFIZER INC. | 2003-03-20 | — | — | US | claimed |
| US-20020016297-A1 | 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives | LINDE ROBERT G (US) | 2002-02-07 | — | — | US | claimed |
| EP-1113008-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | claimed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| EP-3475311-B1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2020-05-13 | — | — | EP | disclosed |
| CN-105724826-B | A kind of prawn feed additive and its application | 集美大学 | 2019-11-26 | — | — | CN | disclosed |
| US-20190175767-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | DEXTECH MEDICAL AB (SE) | 2019-06-13 | — | — | US | disclosed |
| EP-3475311-A1 | MODIFIED DEXTRAN CONJUGATES COMPRISING A LYSINE-UREA-GLUTAMATE PHARMACOPHORE | Dextech Medical AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| CN-109573349-A | A kind of packing method of L-Arginine raw material | 广东盛泰华生物制药有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-109490460-A | A kind of detection method of the L-Arginine in relation to substance | 广东盛泰华生物制药有限公司 | 2019-03-19 | — | — | CN | disclosed |
| EP-2131867-A2 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH KILLING EFFECT ON TUMOR CELLS | Dextech Medical AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009124580-A1 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH BONE SEEKING AND TUMOR KILLING MOIETIES | DEXTECH MEDICAL AB (SE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008107471-A2 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH KILLING EFFECT ON TUMOR CELLS | DEXTECH MEDICAL AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221066-A1 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH KILLING EFFECT ON TUMOR CELLS | DEXTECH MEDICAL AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| US-20030055053-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-20020016297-A1 | 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives | LINDE ROBERT G (US) | 2002-02-07 | — | — | US | disclosed |
| EP-1113008-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055053-A1 | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives | UMPS, UPP1, UGP2 | ENPEP 3032/4885FOLH1 728/4885ALDH1A1 216/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ENPEP 674/4885FOLH1 3628/4885ALDH1A1 548/4885 |
| US-20020016297-A1 | 4-oxo-2- ureido-1,4,5,6,-tetrahydro-pyrimidine derivatives | UMPS, UPP1, NUDT1 | ENPEP 2752/4885FOLH1 549/4885ALDH1A1 237/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | ENPEP 2579/4885FOLH1 4655/4885ALDH1A1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.